A Global Phase III Trial of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
880
about 4.9 years
18+
73 sites in AR, AZ, CA +26
About this study
Researchers are testing whether rilvegostomig, in combination with platinum-based chemotherapy, is effective and safe as a first-line treatment for people whose lung cancer cells express PD-L1. The trial will last about 1785 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Carboplatin
- 2.Take Nab-paclitaxel
- 3.Take Paclitaxel
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
carboplatin, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion, injection, intravenous
Primary: Overall survival (OS), Progression-free survival (PFS)
Secondary: Duration of response (DoR), Landmark overall survival (OS) rates, Landmark progression-free survival (PFS) rates, Overall response rate (ORR), Patient-reported global health status (GHS)/quality of life (QoL), Patient-reported lung cancer symptoms of non-small cell lung cancer (NSCLC), Pharmacokinetic (PK) of rilvegostomig, Time to second progression or death (PFS2)
Oncology